TY - JOUR
T1 - Novel approaches in the treatment of myositis and myopathies
AU - Albayda, Jemima
AU - Christopher Stine, Lisa
N1 - Funding Information:
Dr Christopher-Stine’s work is supported by the NIH (grant number K23-AR-053197).
PY - 2012/10
Y1 - 2012/10
N2 - The inflammatory myopathies are a heterogeneous group of disorders characterized by muscle weakness and inflammation. Although no standard therapeutic guidelines exist, traditional treatment has included corticosteroids and a variety of second-line immunosuppressants. As treatment of refractory disease has been difficult, newer agents and approaches have been used with varying response. The advent of standardized treatment response criteria by the International Myositis Assessment and Clinical Studies (IMACS) group has helped investigators to evaluate and compare clinical trial outcomes in a more rigorous fashion. The use of intravenous immunoglobulin (IVIG), rituximab, biologic agents including tumor necrosis factor (TNF) inhibitors, stem-cell transplantation, gene therapy, and vascular occlusion resistance training are reviewed here. As our understanding of disease pathogenesis at the immunologic, genetic, and molecular level expands, the discovery of novel therapeutic targets hold promise for the successful treatment of these conditions.
AB - The inflammatory myopathies are a heterogeneous group of disorders characterized by muscle weakness and inflammation. Although no standard therapeutic guidelines exist, traditional treatment has included corticosteroids and a variety of second-line immunosuppressants. As treatment of refractory disease has been difficult, newer agents and approaches have been used with varying response. The advent of standardized treatment response criteria by the International Myositis Assessment and Clinical Studies (IMACS) group has helped investigators to evaluate and compare clinical trial outcomes in a more rigorous fashion. The use of intravenous immunoglobulin (IVIG), rituximab, biologic agents including tumor necrosis factor (TNF) inhibitors, stem-cell transplantation, gene therapy, and vascular occlusion resistance training are reviewed here. As our understanding of disease pathogenesis at the immunologic, genetic, and molecular level expands, the discovery of novel therapeutic targets hold promise for the successful treatment of these conditions.
KW - IVIG
KW - gene therapy
KW - idiopathic inflammatory myopathies
KW - novel approaches
KW - rituximab
KW - stem-cell transplantation
UR - http://www.scopus.com/inward/record.url?scp=84869821461&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84869821461&partnerID=8YFLogxK
U2 - 10.1177/1759720X12447705
DO - 10.1177/1759720X12447705
M3 - Review article
C2 - 23024713
AN - SCOPUS:84869821461
SN - 1759-720X
VL - 4
SP - 369
EP - 377
JO - Therapeutic Advances in Musculoskeletal Disease
JF - Therapeutic Advances in Musculoskeletal Disease
IS - 5
ER -